Eli Lilly Blows Away Q3 Earnings Expectations

0
134
jetcityimage / iStock Editorial via Getty Images

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded expectations while raising full-year guidance. The stock traded at $854.08 following the pre-market release, reflecting investor confidence in the company’s accelerating momentum across its core portfolio.

Lilly’s incretin drugs drove the earnings beat. Mounjaro, the company’s diabetes treatment, generated $6.52 billion in quarterly revenue, up 109% year-over-year. Zepbound, its obesity medication, contributed $3.57 billion, surging 184% year-over-year. Combined, these two products accounted for the bulk of revenue growth and explain why the company’s top line expanded 54% to $17.60 billion against consensus expectations of $16.07 billion.

Volume increased 62% in the quarter, signaling sustained…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here